Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma
LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Melanoma Research
09/18/2021
Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma
LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
|
|
08/25/2021
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
August 24, 2021 Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
|
|
08/25/2021
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
|
|
07/22/2021
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
|
|
07/12/2021
Gut Microbes Signal Response to Immune Therapy in Melanoma
(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
|
|
06/30/2021
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
|
|
06/15/2021
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
|
|
06/04/2021
Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
|
|
05/21/2021
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
|
|
04/15/2021
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
|
|
Recent Posts
Feb. 21, 2025
Inheriting Cancer Risk Factors
Feb. 17, 2025
The Heart of Care: Palliative Care and Oncology Social Work
Feb. 14, 2025
Men and Women and Melanoma: Who’s Winning the Battle?
Feb. 06, 2025
Genetic Testing Performed in Melanoma
Jan. 21, 2025